BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — Investor Presentation (October 2024)
25 slides from BioStem Technologies's investor presentation, October 2024
Slide 1: Investor Presentation
Cc ce) =) © —_ Cc co) WY) cD) pes ou Investor — LISTED: BSEM ——
Slide 2: Forward Looking Statements
BIOSTEM TECHNOLOGIES Forward Looking Statements No money or other consideration is being solicited at this time via this communication and, if sent to BioStem Technologies, Inc. (the “Company”) will not be accepted will be promptly returned. A subscription for our securities will be made pursuant to
Slide 3: Mission Statement
ABOUT BIOSTEM TECHNOLOGIES Mission Statement BioStem is a commercial-stage company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care. BioStem’s mission is to be the global leader in regenerative medicine, continuously innovating to
Slide 4: Corporate Highlights
KEY STATISTICS Key Statistics Corporate Highlights As of September 6, 2024 Symbol: Commercial Stage Company • OTC: BSEM ® • Leveraging the Company’s proprietary BioREtain processing method, have 4 placental- Price: derived allograft products on the market for advanced wound care healing • $9.57 Larg
Slide 5: Technology Highlights & Product Offerings
Technology Highlights & Product Offerings
Slide 6: Differentiated Commercial Product Portfolio
POWERED BY BIORETAIN® PROCESSING TECHNOLOGY Differentiated Commercial Product Portfolio WOUND CARE OPTIC 4 202 NUE VE RE river D ü Placental Allograft ü Placental Allograft ü Placental Allograft ü Placental Allograft ü Retain all Native Layers ü Retain all Native Layers ü Retains only Amnion ü Retai
Slide 7: BioStem Product Segments
APPLICATION & REVENUE BioStem Product Segments BioStem Products Have Application in BioStem Revenue by Site of Service Numerous Types of Patient Care Facilities (Inception to Date) 2% Ambulatory Hospital Private 9% Surgical Center Inpatient Office 21% Dermatology Home Wound Health Care Clinic Mobile
Slide 8: Leading Proprietary Technology: Products Powered by BioREtain
HIGHLIGHTS LEADING PROPRIETARY TECHNOLOGY Products Powered by BioREtain® Retaining more of the key BioStem’s Patented, Differentiated Process components of the amniotic tissue: • The patented six-step BioREtain® process preserves the natural integrity of the amniotic tissue factors critical to the h
Slide 9: Patents and Intellectual Property
PATENTS Patents and Intellectual Property Pending Issued Total Placental Tissue 24 3 27 BioREtain 4 1 5 Auxocell 0 37 37 Total 28 41 69 Grouped • Tissue Mincing Apparatus (15) • Clotting (4) International • Systems and Methods for Processing Cells (22) • Joint (4) Pending Applications • Processing a
Slide 10: Placental Donation Network & Allograft Process
PROPRIETARY PRODUCT DEVELOPMENT Placental Donation Network & Allograft Process Placental Donation Network Proprietary Technology 1 2 3 4 5 6 7 Expectant Mom Mom Consents to Delivery of Healthy Donated Placental Microbiology Testing Proprietary 4-Year Shelf-Stable Introduced To Donate and Baby in the
Slide 11: Regulatory Pathway Overview
FDA CLEARED Regulatory Pathway Overview Our Products Biologic Drugs Regulatory Pathway 361 351 Human Tissue When more than minimally When minimally manipulated (i.e., placental tissue) manipulated Indication for Use Homologous use* As indicated by clinical trial Manufacturing Process cGTP CGMP Regul
Slide 12: AATB Accredited, cGTP Manufacturing Facility
MANUFACTURING FACILITY AND CLEAN ROOMS AATB Accredited, cGTP Manufacturing Facility ® Vertically Integrated Manufacturing Facility: • 30+ Years of Allograft Processing Experience • 6,100 Sq/ft Manufacturing Facility • 1,500 Sq/ft ISO clean room space • Expanding to 3,000 Sq/ft ISO space in Q3 – ‘24
Slide 13: Exclusive Commercial and Distribution Partnership with Venture Medical
SALES & MARKETING Exclusive Commercial and Distribution Partnership with Venture Medical About Venture Medical Partnership: • Industry Leader: Premier commercialization master distributor, reseller, and service provider in the U.S. • Expert Salesforce: Extensive, wound healing-focused sales team equ
Slide 14: Clinical Data Initiative Underway for Future Growth
CLINICAL STRATEGY SNAPSHOT Clinical Data Initiative Underway for Future Growth Study Wound Type Product Compared To Design Status Non-Healing Diabetic Foot Multi-center, Randomized, BR-AC-DFU-101 AmnioWrap2 Standard of Care (SOC) In Process Ulcers (DFU) Controlled Trial Non-Healing Diabetic Foot Mul
Slide 15: Chronic Wound Healing Market Trends & Emerging Growth Opportunities
Chronic Wound Healing Market Trends & Emerging Growth Opportunities
Slide 16: BioStem is Addressing a Large Chronic Wound Market
STEADY U.S. GROWTH OPPORTUNITY BioStem is Addressing a Large Chronic Wound Market Chronic Wound Market CAGRs* 19% Wound Types % of Market $3.3B Population Increase in Medicare is Aging Population by 2030 Pressure Ulcers 43% $2.0B $1.3B +7M Diabetic Foot 31% +10% Ulcers $0.9B w/ chronic non-healing V
Slide 17: Financial Performance & Strategic Growth Initiatives
Financial Performance & Strategic Growth Initiatives
Slide 18: Strong Revenue Growth Trend
TRANSFORMATIVE YEAR Strong Revenue Growth Trend $116,400,000 $45,000,000 2024 Has Delivered Record Financial Performance $116,400,000 $40,000,000 $35,000,000 $30,000,000 FIRST HALF $25,000,000 $20,000,000 $16,700,000 $15,000,000 $6,900,000 $10,000,000 $4,400,000 $5,000,000 $0 2021 2022 2023 2024 Bio
Slide 19: 2024 Financial Highlights
HIGHLIGHTS 2024 FINANCIAL HIGHLIGHTS Record Quarterly and First-Half Results Record Q2 revenue of $74.5M FIRST HALF 2024 FIRST HALF 2024 $ 116.4M $ 6.3M Transformative 1H revenue of $116.4M REVENUE NET INCOME AmnioWrap2 continues to be the growth driver Q1 2024 Q2 2024 First Half 2024 2nd consecutiv
Slide 20: Strategic Initiatives in Place for Sustained Revenue Growth
ADVANCING THROUGH CORE GROWTH INITIATIVES Strategic Initiatives in Place for Sustained Revenue Growth Growth Through Strong Revenue Strengthen Strategic Acquisitions Market Expansion Growth & Profitability Reimbursement ü Expecting to broaden ü Expecting strong sales ü Broadening path for ü Focusing
Slide 21: Nasdaq Uplisting Process is Underway
NASDAQ APPLICATION SUBMITTED Nasdaq Uplisting Process is Underway Company Expects to Meet Nasdaq Requirements Across Corporate, Shareholder, and Financial Management Appointments Independent Directors to Board Successful Completion of Comprehensive Audits Form 10 Registration Expected to be Filed Wi
Slide 22: Management Team
ABOUT US Management Team Jason Matuszewski, LSSBB Andrew VanVurst, CTBS Michael Fortunato, CPA Sean McCarrey Wendy Weston, PhD, CTBS Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Commercial Officer Vice President of R&D BioStem Technologies, Inc. | Listed: BSEM 22
Slide 23: Board of Directors
ABOUT US Board of Directors Thomas Dugan Andrew VanVurst, CTBS Jason Matuszewski, LSSBB Brandon Poe Kenneth Warrington, Ph.D. Patrick Daly Chairman of the Board BioStem Technologies, Inc. | Listed: BSEM 23
Slide 24: Well-Positioned to Capitalize on Opportunities Within the Wound Care Market
CONCLUSION Well-Positioned to Capitalize on Opportunities Within the Wound Care Market Superior Products Focused on Working Towards Committed to Leading the Reporting Expanding Payor Revenue Wound Care Clinically Coverage Growth and Industry Significant Data Profitability Over Competitors We Manufac
Slide 25: Thank You.
Thank You. biostemtechnologies.com | [email protected] | (954) 380-8342
BioStem Technologies — Investor Presentation (October 2024) on 6ix